MercuryTM

MercuryTM

Project Mercury was launched to rethink the treatment of Benign Prostatic Hyperplasia (BPH), offering a simple office-based treatment option for patients who need immediate relief from lower urinary tract symptoms (LUTS) with minimal side effects and preserving sexual function.

Unmet Need

Around 50% of men aged 50 and above experience LUTS attributable to BPH. In men over 80 years old, this rises to over 80%. Symptoms include increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream.

Current BPH treatment methods are associated with a multitude of side effects including sexual dysfunction. Treatment with medication is commonly linked to several potential negative side effects such as dizziness, hypotension, erectile dysfunction, and incomplete symptom relief. Surgical treatment options, including the gold standard transurethral resection of the prostate (TURP) or laser surgery, can offer permanent symptom relief, but may lead to irreparable damage to sexual function. Other minimally invasive treatment options may require higher levels of anesthesia, significant use of pain medication, cause permanent damage to the prostatic tissue, and in some cases may require the temporary need for a urinary catheter after the procedure.

Our Solution

Project Mercury is designed to widen the narrowed prostatic urethra tissue creating an open urethral lumen for normal urinary flow. This structure can be deployed using a commercially available standard flexible cystoscope in clinics and physicians'offices.

KOL and physicians have positive comments on the features of Mercury design:

  • Office-based procedure: performed by commercially available standard flexible cystoscopy under local anesthesia
  • Reversible procedure: Can be done before, during, or after any other BPH treatment
  • Safe and Effective procedure: Improved patient journey with minimal pain, no catheter and preserves sexual function

Medeon firmly believes Project Mercury represents a significant leap forward in the treatment of LUTS caused by BPH. Clinical studies and regulatory approvals are ongoing.